Utility of cardiac magnetic resonance in assessing right-sided heart failure in sarcoidosis

BMC Medical Imaging

Gemma A Figtree⁴  Stuart M Grieve¹  Anthony Gill²  Michael Ward⁴  Jacob Lønborg³ 

[1] Department of Radiology, Royal Prince Alfred Hospital, Sydney, Australia;Department of Pathology, Royal North Shore Hospital, Sydney, Australia;Department of Cardiology, Rigshospitalet, Copenhagen, Denmark;Department of Cardiology, Royal North Shore Hospital, St Leonards, NSW 2065, Australia

关键词: Cardiomyopathy;    Heart failure;    Cardiac magnetic resonance;    Myocardial sarcoidosis;   

Others  :  1091448
DOI  :  10.1186/1471-2342-13-2

 received in 2012-05-22, accepted in 2012-12-31,  发布年份 2013

【 摘 要 】

Background

Cardiac involvement in sarcoidosis is associated with a poor prognosis. In patients with right sided heart failure, differentiating between cor-pulmonale, or cardiac sarcoidosis has important implications to management.

Case presentation

We present the case of a patient with severe but stable pulmonary sarcoidosis and new onset right sided heart failure despite only mild elevations of pulmonary artery pressure. CMR demonstration of extensive right ventricular fibrosis with associated dilatation and hypokinesis was a key finding for prognosis and management of the patient.

Conclusion

Cardiac magnetic resonance (CMR) is the preferred investigation in the diagnosis of cardiac sarcoidosis, allowing assessment of myocardial inflammation and fibrosis, as well as function, in a manner not matched by other technologies.

【 授权许可】

   
2013 Lønborg et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Dubrey SW, Falk RH: Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis 2010, 52:336-346.
• [2]Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN, Prystowsky S: Cardiac sarcoidosis. Am Heart J 2009, 157:9-21.
• [3]Roberts WC, McAllister HA Jr, Ferrans VJ: Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 1977, 63:86-108.
• [4]Soejima K, Yada H: The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009, 20:578-583.
• [5]Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ: Detection of myocardial damage in patients with sarcoidosis. Circulation 2009, 120:1969-1977.
• [6]Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, Crijns HJ: Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005, 45:1683-1690.
• [7]Figtree GA, Lonborg J, Grieve SM, Ward MR, Bhindi R: Cardiac magnetic resonance imaging for the interventional cardiologist. JACC Cardiovasc Interv 2011, 4:137-148.
• [8]White SK, Sado DM, Flett AS, Moon JC: Characterising the myocardial interstitial space: the clinical relevance of non-invasive imaging. Heart 2012, 98:773-779.
• [9]Azuma A, Kim HW, Parker M, Kim RJ: Prognostic value of delayed enhancement cardiovascular magnetic resonance in patients with sarcoidosis. J Cardiovasc Magn Reson 2012, 14(Suppl 1):O13. BioMed Central Full Text